Other investigational drugs with potential therapeutic value in NAFLD include antileukotriene agents [210], GPCR modulators [211], anti-IL mABs [212], IL22 axis modulators [213], purinergic receptor agonists [214], antioxidants [215], antisense oligonucleotides [216], multitarget epigenetic regulators [217], and many more. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.